Safety profile of zolpidem: Two studies in 3805 patients with Swiss practitioners;Sicherheitsprofil von zolpidem: Zwei studien mit 3805 patienten bei Schweizer praktikern

Praxis

Volumn 88, Issue 25-26, 1999, Pages 1120-1127

  Ganzoni, E ^a   Gugger, M ^b  

^a Departement fur Innere Medizin   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adverse event; Clinical trial; Hypnotic; Insomnia; Zolpidem

Indexed keywords

ZOLPIDEM;

ARTICLE; CLINICAL TRIAL; CONFUSION; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; SOMNOLENCE; SWITZERLAND; VERTIGO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDINES; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 0033600248     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Haldemann R., Good M., Holsboer-Trachsler E.: Epidemiologische Studie über Schlafstörungen bei Patienten in Schweizer Allgemeinpraxen. Praxis 1996; 85: 1656-1662. (Pubitemid 127565422)
2. Kales A., Kales J.D.: Evaluation and treatment of insomnia. Oxford, New York: Oxford University Press, 1984.
3. Dement W.C., Pelayo R.: Public health impact and treatment of insomnia. Eur Psychiatry 1997;12(1):31s-39s. (Pubitemid 27061098)
4. Kupfer D.J., Reynolds C.F.: Management of insomnia. N Engl J Med 1997;336(5):341-6.
5. Hajak G., Müller-Popkes K., Riemann D., Mayer G., Lauer C. et al.: Psychologische, psychotherapeutische und andere nichtpharmakologische Therapieformen zur Behandlung der Insomnie. Fortschr Neurolog Psychiat 1997;65:133-144. (Pubitemid 27165399)
6. Hohagen F.: Nonpharmacological treatment of insomnia. Sleep 1996;19(8):S50-51.
7. Borbély A.A.: Pharmakotherapie von Schlafstörungen. Therapeutische Umschau 1993; 50(10):709-712.
8. Roth T.: Management of insomniac patients. Sleep 1996;19(8):S50-51.
9. Bianchetti G., Dubruc C., Thiercelin J.F. et al.: Clinical pharmacokinetics of zolpidem in various physiological and pathological conditions. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: A novel experimental and therapeutic approach. New York: Raven Press, 1988: 155-163.
10. Thénot J.P., Herrmann P., Durand A. et al.: Pharmacokinetics and metabolism in various animal species and in humans. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: A novel experimental and therapeutic approach. New York: Raven Press, 1988: 139-153.
11. Langer S.Z., Arbilla S.: Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes. Pharmacology Biochemistry and Behaviour 1988; 29: 763-766. (Pubitemid 19260922)
12. Benavides J., Peny B., Ruano D., Victoria J., Scatton B.: Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res 1993; 604(1-2): 240-250. (Pubitemid 23080121)
13. Zivkovic B., Perrault G., Morel E. et al.: Comparative pharmacology of zolpidem and other hypnotics and sleep inducers. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: A novel experimental and therapeutic approach. New York: Raven Press, 1988: 97-109.
14. Zivkovic B., Perrault G., Morel E., Sanger D.J.: Neuropsychopharmacological profile of zol-pidem, a new imidazopyridine hypnotic. In: Insomnie et Imidazopyridines. Amsterdam: Excerpta Medica, 1990: 219-230.
15. Maarek L., Cramer P., Attali P., Coquelin J.P., Morselli P.L.: The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res 1992; 20: 162-170.
16. Langtry H.D., Benfield P.: Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutical potential. Drugs 1990; 40: 291-313.
17. Walsh J.K., Schweitzer P.K., Muehlbach M.J., Sugerman J.L.: Experimental phase-advance as a model of transient insomnia and effects of zolpidem. Sleep Research 1988; 17: 267.
18. Kryger M.H., Steljes D., Pouliot Z., Neufeld H., Odynski T.: Subjective versus objective evaluation of hypnotic efficacy: Experience with zolpidem. Sleep 1991; 14(5): 399-407.
19. Undén M., Roth Schechter B.: Next day effects after nighttime treatment with zolpidem: a review. Eur Psychiatry 1996;11(suppl 1):21s-30s.
20. Kales A., Soldatos C.R., Bixler E.O., Kales J.D.: Rebound Insomnia and rebound anxiety: a review. Pharmacology 1983;26:121-137. (Pubitemid 13188487)
21. Monti J., Monti D., Attali P.:Comparative hypnotic and withdrawal effects of zolpidem, triazolam and placebo in insomniac patients. In: Abstracts of the 11th European Congress of the Euro-pean Sleep Research Society, Finland 5th-10th July 1992. J Sleep Res 1992; 1 (Suppl 1): 153.
22. Kummer J., Gündel L., Linden J.: Long-term polysomnography study of the efficacy and safety of zolpidem in elderly psychiatric inpatients with insomnia. J Int Med Res 1993; 21: 171-184. (Pubitemid 23355470)
23. Lavoisy J., Zivkovic B., Benavides J., Perrault G.H., Robert P.: Apport du zolpidem dans la prise en charge des troubles du sommeil. L'Encéphale 1992; 18: 379-392.
24. Wyss P., Radovanovic D., Meier-Abt P.J.: Akute Überdosierungen mit Zolpidem (Stilnox(). Schweiz Med Wochenschr 1996;126(18):750-756. (Pubitemid 26155387)
25. Ganzoni E., Santoni J.P., Chevillard V., Sébille M., Mathy B.: Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland. J Int Med Res 1995;23:61-73.
26. Registration under condition («monitored release»). In: guidelines concerning requirements of a documentation for registration of human drugs (registration guidelines). Bern, Interkantonale Kontrollstelle für Heilmittel (IKS) 16th December 1977, revised 23rd May 1985: article 9.
27. Black N.: Why we need observational studies to evaluate the effectiveness of health care. Brit Med J 1996;312:1215-1218.
28. Waller P.C., Wood S.M., Langman M.J.S., Breckenridge A.M., Rawlins M.D.: Review of company postmarketing surveillance studies. Brit Med J 1992; 304: 1470-1472.
29. Inman W., Pearce G.: Prescriber profile and post-marketing surveillance. The Lancet 1993; 342: 658-661. (Pubitemid 23271508)
30. Ambien( (zolpidem tartrate). Prescribing information in the United States of America. G.D. Searle & Co. (Chicago) 1993.
31. Paty J., Barthouil P.: Efficacy and tolerance of a shift from benzodiazepine hypnotic drugs to zolpidem 10 mg/d in chronic insomniacs: an open study based on general practitioners. In Book of abstracts, WFSRS, Cannes, France, 21st-25th September; Sleep Research 1992; 20A: 370.
32. Quera Salva T., Borderis P., Moreau J. et al.: The efficacy of zolpidem during and after a progressive shift from benzodiazepines (BZD) hypnotics in elderly chronic insomniac patients. In: Abstracts of the 11th European Congress of the ESRS, Helsinki, Finland, 5th-10th July. J Sleep Res 1992; (Suppl 1): 187.
33. Chaumet-Riffaud A.E., Desforges C., Lavoisy J.: Review of the postmarketing surveillance experience collected with zolpidem during the first-three years after launch in Europe. In: Abstracts of the 11th European Congress of the ESRS, Helsinki, Finland, 5th-10th July 1992. J Sleep Res 1992; 1(Suppl 1): 80.
34. Godderis J., Cluydts R.: Substitution from a benzodiazepine to zolpidem in elderly insomniacs: preliminary data. In: Abstracts of the 11th European Congress of the ESRS, Helsinki, Finland, 5th-10th July 1992. J Sleep Res 1992; 1(Suppl 1): 83.
35. Cluydts R., De Roeck J., Jolie A.: A three week multicentre general practitioner study of zolpidem in 651 patients with insomnia. Acta Ther 1993; 19(1): 73-91. (Pubitemid 23020319)
36. Ciapparelli A., Colombo C., Cuccato G., Levi-Minzi A., Lorizio A., Maggioni M., Siciliano G., Silvestri R., Biondi F., Casadei G.L.: Shift to zolpidem, a new imidazopyridine hypnotic, in insomniac patients previously taking benzodiazepine hypnotics. Minerva Psichiatr 1991; 32: 3-12.
37. Biondi F., Casadei G.L.: Results of a multicenter trial with the hypnotic zolpidem in 1152 insomniac patients. Curr Ther Res 1994; 55(3): 262-74. (Pubitemid 24134804)
38. Ahrens J.: Behandlung von Schlafstörungen mit Zolpidem. Wirksamkeit ohne Abhängigkeitspotential. Therapiewoche 1993; 43(38):1942-1944.
39. Licciardello L., Licini P.: Safety and efficacy of zolpidem therapy in sleep disorders: a multi center trial in hospitalized patients. Curr Ther Res 1992;52:652-658.
40. Roger M., Attali P., Coquelin J.P.: Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993;15:127-135.
41. Hajak G., Khan-Boluki J.: Zolpidem Postmarketing Surveillance (PMS) on 16944 patients. Eur Psychiatry 1996;11(4 Suppl):369S.
42. Peeters K., Boucau I., De Bouyalsky I.: Efficacy and safety of a onemonth treatment with zolpidem in middle-aged and elderly insomniacs. Acta Therapeutica 1997;23:5-19. (Pubitemid 27285345)
43. Cavallaro R., Regazzetti M.G., Covelli G., Smeraldi E.: Tolerance and withdrawal with zolpidem. Lancet 1997;342:374-375.
44. Gericke C.A., Ludolph A.C.: Chronic abuse of zolpidem. JAMA 1994;272(22):1721-1722. (Pubitemid 24371987)
45. Wesson D.R., Ling W., Smith D.E.: Zolpidem: an addiction medecine perspective. California Soc Addic Med News 1994:14-15.
46. Thome J., Ruchsow M., Rösler M., Becker T.: Zolpidem- Abhängigkeit und Depression im Senium. Psychiat Prax 1995;22:165-166.
47. Watsky E.: Management of zolpidem withdrawal. J Clin Psychopharmacol 1996;16(6):459.
48. Bottlender R., Schütz C., Möller H.J., Soyka M.: Zolpidem dependence in a patient with former polysubstance abuse. Pharmacopsychiat 1997;30:108. (Pubitemid 27232497)
49. Ravishankar A., Carnwath T.: Zolpidem tolerance and dependence -two case reports. J Psychopharmacol 1998;12(1):103-104. (Pubitemid 28143012)
50. Guerault E., Chaumet-Riffaud A., Morselli P., Attali P.: Neurological adverse event profile in the elderly with zolpidem 5 and 10 mg: a retrospective evaluation of european phase II and III studies. J Sleep Research 1992;1(suppl 1);89.
51. Roger M., Frattola L.: Subjective assessment of the efficacy of zolpidem in the elderly. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Freeman H., Puech A.J., Roth T., editors. Elsevier, Paris 1996:183-194.
52. Girault C., Muir J.F., Mihaltan F., Borderies P., De la Giclais B., Verdure A., Samson-Dollfus D.: Effects of repeated administration of zolpidem on sleep, diurnal and nocturanl respiratory function, vigilance, and physical performance in patients with COPD. Chest 1996;110(5):1203-1211. (Pubitemid 26380474)
53. Strolle P.J., Rogers R.M.: Obstructive sleep apnea. N Engl J Med 1996;334(2):99-104.